PRLD Prelude Therapeutics Incorporat
$3.98▲ +2.58%
Healthcare
Other
Volume 104.1K
Avg Volume (10D) 505.3K
Key Metrics & Fundamentals
Market Cap
$317.62M
P/E Ratio
–
Div Yield
0.00%
52W Range
1.17 - 6.83
% vs 50 MA
-15.14%
% vs 200 MA
-2.62%
RSI-14
50.0
MACD Histogram
+0.0800
Beta (1Y vs SPY)
1.91
Free Cash Flow
-$15.57M
Gross Rev
$5.70M
Gross Profit
$5.70M
EBITDA
-$15.10M
COGS
–
Operating Exp
$21.16M
Operating Income
-$15.45M
EBIT
-$15.45M
Pretax Income
-$13.92M
Net Income
-$13.92M
EPS (Diluted)
-0.14
Price & Volume History
Loading chart…
Recent News
Can Tenet Healthcare Beat Q3 Earnings on Ambulatory Care Strength?
Zacks · Oct 27, 2026 11:56 AM ET
Prelude Therapeutics Spotlights JAK2, KAT6A Programs and Potential $100M Incyte Option
MarketBeat · Oct 22, 2026 11:02 PM ET
Prelude Therapeutics to Participate in the Chardan Healthcare Conference
GlobeNewswire · Oct 16, 2026 4:01 PM ET
Down 27.4% in 4 Weeks, Here's Why Prelude Therapeutics (PRLD) Looks Ripe for a Turnaround
Zacks · Oct 16, 2026 8:35 AM ET
Eli Lilly (LLY) Reported One Year Steroid Free Control In Difficult IBD
Simply Wall St. · Oct 15, 2026 2:13 PM ET
Prelude Therapeutics Teams Up With Lilly To Test Experimental Breast Cancer Drug In Phase 1 Trial
Stocktwits · Oct 13, 2026 1:11 PM ET
Prelude Therapeutics, Eli Lilly to Study Breast Cancer Drug Combinations in Phase 1 Trial
MT Newswires · Oct 13, 2026 7:39 AM ET
Prelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio® and Inluriyo® in Patients with HR+/HER2- Breast Cancer
GlobeNewswire · Oct 13, 2026 7:01 AM ET
Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
GlobeNewswire · Sep 11, 2026 7:01 AM ET
Prelude Therapeutics Cleared by FDA for Phase 1 Breast Cancer Drug Trial
MT Newswires · Sep 10, 2026 7:54 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See PRLD's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.